Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Syncona Limited
Deal Size : $28.0 million
Deal Type : Series A Financing
Mosaic Therapeutics Closes $28m Series A Funding and Appoints Brian Gladsden as CEO
Details : The Series A funding will be used to further advance Mosaic’s pipeline of targeted oncology therapies for biomarker-stratified populations, progressing its lead programmes through preclinical development to IND-enabling studies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 04, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Syncona Limited
Deal Size : $28.0 million
Deal Type : Series A Financing